Due to the site upgrade, your MY ACCOUNT logins will need to be updated. Please access Forgot Your Password to make this change. If you do not have an account, click here.

GliSODin reverses thickening of the carotid arteries remarkably well

Mar 16, 2007

As we age the lining of the carotid arteries thicken (intima media thickening). This just like hardening of the arteries increases the risk of stroke and heart attack. In this new, 3-year long study, young adult patients between the ages of 40 to 46 had the thickness of their carotid artery lining measured via precise Ultrasound-B Imaging; a technique accepted world wide for detecting earlier stages of arterial damage.
The patients had a level of thickening of their artery lining that was too high for their age bracket; this is because they had metabolic syndrome (overweight, high blood pressure, high cholesterol, blood sugar issues, etc) and are at high-risk for developing heart disease and diabetes. They all also had a low antioxidant status.

The patients were split into two groups and both were placed on a heart-healthy diet that was rigorously overseen by clinicians (Lyon Heart Diet). Over the next two years one group was supplemented with 500mg of GliSODin each day and the other group stayed on the diet but without the supplement. At the end of the study the diet only group saw no change in antioxidant status and they had a slight but significant thickening of the carotid artery lining. This is significant because it shows that even though diet and lifestyle are modified, if there is existing inflammation in the blood vessel walls the life-style/diet changes are not enough to halt the progression of damage.

However, in the group that added GliSODin supplementation to their diet the antioxidant status significantly improved with a corresponding reduction in lipid peroxidation. Incredibly, the GliSODin group showed a significant reduction in the thickening of the lining of their carotid arteries within the first year of supplementation that improved to a highly significant reduction in the thickening of the carotid artery lining by the second year; the GliSODin didn?t just prevent further thickening, GliSODin actually reversed existing cardiovascular damage. The study was performed by researchers from the National Association of Medical Prevention in France, and is published in the current issue of the journal European Annals of Allergy and Clinical Immunology, 2007, 39(2).

More evidence that EGCG may help prevent invasive bladder cancer

In previous studies in different animals, EGCG from Green Tea inhibited the growth of bladder tumors. In a laboratory test, EGCG even at modestly low levels inhibited the growth of invasive bladder cancer cells by 50%. EGCG also inhibited the ability of the bladder cancer to invade and spread. When human bladder cancer was transplanted into mice, feeding them EGCG prior to and during the establishment of bladder cancer decreased the growth of the tumor by greater than 50% with no detectable toxicity to the animals. The study was performed at the Lahey Clinic Medical Center in Massachusetts and is published in the March 8th. 2007 issue of the Journal of Cellular Biochemistry.

Using EGCG with Celebrex strongly inhibits the growth of prostate cancer tumors; allowing for a lower-safer dosage of Celebrex

COX-2 inhibitors are commonly prescribed to treat the pain and inflammation of arthritis. COX-2 inhibitors are promising cancer preventing agents. However, toxicity concerns show that other-newer strategies are needed; recently even Celebrex has been shown to increase the risk of heart attack. One approach to overcome this limitation is to use lower doses of COX-2 inhibitors in combination with other established agents with complementary mechanisms.

In this study mice lacking immune function were implanted with human prostate cancer. If EGCG was given alone it inhibited the growth of prostate tumors by 42%, Celebrex inhibited their growth by 57%. However, adding the two together (Celebrex with EGCG) inhibited the growth of the prostate cancer tumors by 81%. The dosage of Celebrex needed to achieve this inhibition of tumor growth was just 200mg because of the addition of Green Tea. When Celebrex was used alone for colon cancer prevention they typically had to use an 800mg dose.

The combination of Green Tea with Celebrex also lowered PSA levels and growth factor levels significantly. The study is published in the March 1st, 2007 issue of the journal Clinical Cancer Research.